Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens

被引:159
作者
Ramphal, R [1 ]
机构
[1] Univ Florida, Dept Med, JHMHC, Div Infect Dis, Gainesville, FL 32610 USA
关键词
D O I
10.1086/383048
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The etiology of bacteremia in febrile neutropenic patients in the past few decades has shifted from gram-negative to gram-positive organisms. Potential reasons include the use of indwelling catheters, local environmental conditions, and the administration of specific antibiotic agents, especially as prophylaxis. Other factors may emerge from new studies, such as the categorization of febrile neutropenic patients into groups at low risk and at high risk of developing serious complications, continuing changes in resistance in the community, the use of antibiotic-coated catheters, and future changes in cytotoxic chemotherapy or antineoplastic therapy. In addition, there has been a drift in susceptibility patterns, with resistance issues seen in the general population of hospitalized patients now emerging in febrile neutropenic patients, as well as some issues specific to these patients. These changes affect empirical therapy as it was practiced a decade ago. Among the most commonly used agents, cefepime and carbapenems continue to show the highest rates of in vitro susceptibility, providing coverage against most gram-positive and gram-negative organisms and reducing the need for glycopeptides. Older agents continue to show degradation of their effectiveness. Among Pseudomonas aeruginosa strains, susceptibility to all agents continues to decline.
引用
收藏
页码:S25 / S31
页数:7
相关论文
共 43 条
[1]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P902
[2]  
Ariffin H, 2000, Int J Infect Dis, V4, P21, DOI 10.1016/S1201-9712(00)90061-4
[3]   Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa:: regional results from SENTRY Antimicrobial Surveillance Program (1998-99) [J].
Bell, JM ;
Turnidge, JD ;
Gales, AC ;
Pfaller, MA ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 42 (03) :193-198
[4]  
Bodey G P, 1977, Curr Probl Cancer, V1, P1
[5]   The treatment of febrile neutropenia: From the Dark Ages to the present [J].
Bodey, GP .
SUPPORTIVE CARE IN CANCER, 1997, 5 (05) :351-357
[6]   EMERGENCE OF QUINOLONE-RESISTANT ESCHERICHIA-COLI BACTEREMIA IN NEUTROPENIC PATIENTS WITH CANCER WHO HAVE RECEIVED PROPHYLACTIC NORFLOXACIN [J].
CARRATALA, J ;
FERNANDEZSEVILLA, A ;
TUBAU, F ;
CALLIS, M ;
GUDIOL, F .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (03) :557-560
[7]   BACTEREMIA DUE TO VIRIDANS STREPTOCOCCI THAT ARE HIGHLY RESISTANT TO PENICILLIN - INCREASE AMONG NEUTROPENIC PATIENTS WITH CANCER [J].
CARRATALA, J ;
ALCAIDE, F ;
FERNANDEZSEVILLA, A ;
CORBELLA, X ;
LINARES, J ;
GUDIOL, F .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (05) :1169-1173
[8]   Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients [J].
Collin, BA ;
Leather, HL ;
Wingard, JR ;
Ramphal, R .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) :947-953
[9]   Epidemiology and risk factors for gram-positive coccal infections in neutropenia: Toward a more targeted antibiotic strategy [J].
Cordonnier, C ;
Buzyn, A ;
Leverger, G ;
Herbrecht, R ;
Hunault, M ;
Leclercq, R ;
Bastuji-Garin, S .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :149-158
[10]   A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia [J].
Del Favero, A ;
Menichetti, F ;
Martino, P ;
Bucaneve, G ;
Micozzi, A ;
Gentile, G ;
Furno, P ;
Russo, D ;
D'Antonio, D ;
Ricci, P ;
Martino, B ;
Mandelli, F .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1295-1301